Ann: Updated Company Presentation, page-3

They added two slide and re-worded a bit from the AGM presentation, this addition is interesting as to why they add it in, wonder who they're trying to get interest from?;

Value Creation Potential of ATL1102 for DMD - Sarepta Therapeutics
• Exondys 51 (Sarepta) was approved by the FDA in late 2016 under the accelerated approval pathway based on the surrogate endpoint of dystrophin increase in skeletal muscle observed in some Exondys 51-treated patients
• Prior to the approval of Exondys 51, Sarepta had a market capitalisation ( m / c ) of ~US$60m (July 2012). Following FDA approval of Exondys 51 Sarepta’s m/c peaked at US$3.3Billion (current m/c US$9Billion)
• Exondys 51 is the first FDA approved treatment for DMD, however is only useful in 13% of boys with the exon 51 mutation, where as inflammation (the target of ATL1102 in DMD) contributes to disease progression in all DMD patients
• Cost per patient of Exondys 51 is US$300K/year
• 3rd Qtr 2018 total net revenue for Exondys 51 was US$78.5 million
• Notably, Mr William Goolsbee, ex Chairman of Sarepta, is a non-executive director of ANP and Exondys 51 inventor, Professor Steve Wilton (Murdoch University, Perth) is a member of the Scientific Advisory Board